Stock Commentary - New York week to April 20, 2009
22 April 2009
NEW YORK: equities fell on the first trading day of the reporting period to April 20, on negative economic data, but then rebounded, with the Dow Jones again above the psychologically-important 8,000 level, though plunging on the last day and losing this, dragged lower by a particularly bad day in the banking sector. The Dow was down 2.7% week on week. Drug and biotechnology stocks were mixed, with 17 of those tracked rising and 19 falling, as the first-quarter results season sprang into life.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
A clinical-stage biopharmaceutical company developing first-in-class programmed off-the-shelf cellular immunotherapies for cancer and autoimmune diseases.
Stock Commentary - New York week to April 20, 2009
NEW YORK: equities fell on the first trading day of the reporting period to April 20, on negative economic data, but then rebounded, with the Dow Jones again above the psychologically-important 8,000 level, though plunging on the last day and losing this, dragged lower by a particularly bad day in the banking sector. The Dow was down 2.7% week on week. Drug and biotechnology stocks were mixed, with 17 of those tracked rising and 19 falling, as the first-quarter results season sprang into life.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Company News Directory
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
| Headless Content Management with Blaze